MAP2K7 and non-small cell lung carcinoma: Because most PTPN11/Shp2 inhibitors have limited potency against mutated Shp2 [25], along with non-specific effects on other PTPs, in this study, we wanted to investigate both direct and indirect targeting strategies using Shp2, MEK, and PI3K inhibitors in PTPN11-mutated NSCLC.